Clarius Group LLC Sells 2,762 Shares of Novo Nordisk A/S (NYSE:NVO)

Clarius Group LLC lowered its stake in Novo Nordisk A/S (NYSE:NVO) by 20.2% during the 4th quarter, HoldingsChannel reports. The firm owned 10,930 shares of the company’s stock after selling 2,762 shares during the period. Clarius Group LLC’s holdings in Novo Nordisk A/S were worth $940,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in NVO. Aaron Wealth Advisors LLC boosted its stake in shares of Novo Nordisk A/S by 6.9% in the 4th quarter. Aaron Wealth Advisors LLC now owns 21,572 shares of the company’s stock worth $1,856,000 after buying an additional 1,396 shares during the last quarter. IAM Advisory LLC boosted its position in Novo Nordisk A/S by 1.3% in the fourth quarter. IAM Advisory LLC now owns 16,836 shares of the company’s stock worth $1,448,000 after purchasing an additional 222 shares during the last quarter. Riversedge Advisors LLC grew its stake in shares of Novo Nordisk A/S by 7.0% during the 4th quarter. Riversedge Advisors LLC now owns 3,768 shares of the company’s stock valued at $324,000 after purchasing an additional 245 shares during the period. Ameritas Advisory Services LLC increased its position in shares of Novo Nordisk A/S by 453.3% during the 4th quarter. Ameritas Advisory Services LLC now owns 11,000 shares of the company’s stock valued at $946,000 after purchasing an additional 9,012 shares during the last quarter. Finally, HB Wealth Management LLC boosted its holdings in shares of Novo Nordisk A/S by 5.4% in the fourth quarter. HB Wealth Management LLC now owns 17,122 shares of the company’s stock worth $1,473,000 after buying an additional 875 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

NVO has been the topic of several recent research reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Finally, UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $140.20.

Novo Nordisk A/S Stock Performance

Shares of NYSE:NVO opened at $78.74 on Friday. The firm has a fifty day simple moving average of $97.76 and a two-hundred day simple moving average of $117.23. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $353.33 billion, a P/E ratio of 25.48, a PEG ratio of 0.92 and a beta of 0.45. Novo Nordisk A/S has a 52 week low of $78.17 and a 52 week high of $148.15.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.